Skip to content
MARKETS / NASDAQ / BMGL
NASDAQ · SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE · SMALL CAP

Basel Medical Group Ltd. BMGL

2 fiscal years on record · SGD · FY2024 reported · SEC filings only
SGD 11.3M
▲ 12.6% YoY
SGD -10.6M
▼ 613.1% YoY
SGD -4.6M
▼ 283.9% YoY
In brief

What this company does

In February 2025, Basel Medical Group Ltd listed successfully on NASDAQ with the goal to grow into a more international medical group, transcending the role of a conventional healthcare provider with a vision for innovation, growth and far-reaching impact. Following such completion, Bethesda Medical became a wholly owned indirect subsidiary of Basel Medical Group Ltd. Basel Medical Group Ltd, or “Basel Medical”, is a BVI business company incorporated in the BVI. Basel Medical serves as the holding company of our Group and we conduct our operations through our operating subsidiaries based in Singapore. We provide a wide spectrum of general and subspecialized orthopedic including but not limited to trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. We currently have 13 medical practitioners in our Group, comprising 4 specialists and 9 general practitioners.

Written from the business description in Basel Medical Group Ltd's annual report to the U.S. Securities and Exchange Commission, filed 13 March 2026. Every sentence was checked against that document before publication.

Growth
SGD 11.3M
Revenue, FY2024 · full 2-year series below
Revenue SGD M Net income SGD M
FY2024 · Revenue 11.3 · Net income -10.6
4M8M-4M-8M20232024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−94 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Net -94.0%
10%20%-50%20232024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow SGD M
FY2024 · FCF -4.6
1M2M-2M-4M20232024

Total assetsSGD 18.7M
CashSGD 3.0M
Current ratio1.31×

Not available: we don't have the total debt figure for this period.

The 2-year record
2 fiscal years
Every figure from documents filed with the SEC · SGD
row low → row highnegative
Metric 20242023
Revenue SGD B0.00.0
Operating income SGD B··
EBITDA SGD B··
Income tax SGD B−0.00.0
Net income SGD B−0.00.0
Free cash flow SGD B−0.00.0
EPS, diluted SGD −0.570.13
Dividend / sh SGD ··
Payout %··
ROE %··

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures in 8 reconciliationsAUDITED

Reconciled in 1 of 19 fiscal years. 68 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityServices-Offices & Clinics of Doctors of Medicine
Listed onNASDAQ
Incorporated inoutside the United States — SEC code D8
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2023

Share this section

Download image